Repligen Corp. 10-Q Summary: Quarter Ended September 30, 2004
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2004, and the six-month period ended on that date. Repligen Corporation is a biotechnology company developing novel biological products for neuropsychiatric disorders and autoimmune diseases. The company funds its therapeutic development through profits from its specialty pharmaceutical products, specifically Protein A (for process chromatography) and SecreFlo (for gastroenterology).
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2004 | Six Months Ended Sep 30, 2004 |
|---|---|---|
| Total Revenue | $1,296,432 | $4,105,886 |
| Gross Profit | $593,103 (46% margin) | $2,269,964 (55% margin) |
| Net Loss | $(1,718,629) | $(2,363,715) |
| Net Loss Per Share (Basic/Diluted) | $(0.06) | $(0.08) |
| Cash and Cash Equivalents | $3,952,714 (as of Sep 30, 2004) | |
| Total Marketable Securities | $19,851,227 (Current: $15.3M; Long-term: $4.5M) | |
| Working Capital | $18,178,000 | |
| Debt | No long-term debt; Long-term liabilities of $78,298 |
Material Changes vs. Prior Period
- Revenue: For the three months ended September 30, 2004, revenue decreased 9% to $1.30 million compared to $1.42 million in the prior year, driven by a decline in Protein A sales. However, for the six-month period, revenue increased 18% to $4.11 million compared to $3.48 million, due to increased demand for Protein A and SecreFlo.
- Operating Expenses: Total operating expenses decreased 17% ($499,000) for the quarter and 23% ($1.41 million) for the six months compared to the prior year periods. This was primarily due to reduced clinical trial and material expenses in R&D.
- Liquidity: Total cash and marketable securities decreased slightly to $24.0 million from $24.9 million at the end of the fiscal year (March 31, 2004). Working capital increased significantly to $18.2 million, largely due to the reclassification of long-term marketable securities to short-term.
- Customer Concentration: For the six months ended September 30, 2004, two customers accounted for approximately 61% and 10% of total revenues, respectively.
Outlook, Risks, and Contingencies
- Supplier Dispute: Repligen relies on a single supplier, ChiRhoClin, Inc., for SecreFlo. Repligen terminated the licensing agreement in February 2004 for breach, seeking recovery of approximately $5 million. ChiRhoClin has filed a counterclaim seeking $1.75 million in milestone payments and royalty disputes. The outcome could materially impact future revenues and cash flows.
- Future Losses: Management expects to continue incurring operating losses for the foreseeable future as it invests in R&D for therapeutic candidates (secretin, uridine, CTLA4-Ig).
- Accounting Changes: The company is evaluating the impact of the proposed FASB Statement 123R regarding share-based payments, which may require fair value measurement of stock options effective June 15, 2005.
- Market Risk: The company holds significant marketable securities. A hypothetical 100 basis point increase in interest rates would result in an approximate $129,000 decrease in the fair value of these investments.
Investor Verification Checklist
- Verify the status and potential financial impact of the ongoing litigation with ChiRhoClin regarding the SecreFlo supply agreement.
- Monitor the timeline and results of clinical trials for therapeutic candidates (secretin, uridine, CTLA4-Ig) to assess future revenue potential.
- Review the concentration of revenue from top customers (61% from one customer in the six-month period) and the stability of these relationships.
- Assess the sufficiency of current cash and marketable securities ($24 million) to fund operations given the expectation of continued losses.
- Confirm the impact of the upcoming adoption of FASB Statement 123R on future reported net loss and stock-based compensation expenses.